Thursday, December 31, 2009
Ovarian metastases from breast cancer
"Ovarian disease (cancer) was diagnosed at a median of 5 years after breast cancer. Seventy-five percent of patients were asymptomatic, and advanced-stage pelvic extent or extra-abdominal metastases were observed in 41.5% of patients. The median survival was 3 years..."
Safety Considerations and Potential Interactions of Vitamins: Should Vitamins Be Considered Drugs?
"...A, E, D can cause serious adverse events."
Identifying novel autoantibody signatures in ovarian cancer
CONCLUSIONS: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.
full free access EDITORIAL: Designing Early Detection Programs for Ovarian Cancer -- JNCI
free full access: Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- JNCI
Note: small study, did not include family history of colorectal cancer (Lynch Syndrome); clear cell ovarian subtype
THE RESEARCH ARTICLE:
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- Anderson et al., 10.1093/jnci/djp438 -- JNCI Journal of the National Cancer Institute
Wednesday, December 30, 2009
Assessing lead time of selected ovarian cancer biomarkers | Science Codex
Assessing lead time of selected ovarian cancer biomarkers
"Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only in the last year prior to diagnosis. The stage of the cancer at the time of marker elevation is not known.
CA125, HE4, mesothelin, B7-H4, decoy receptor 3, and spondin-2 have been identified as potential ovarian cancer biomarkers, but their behavior in the pre-diagnostic period, with the exception of CA125, has not been evaluated previously."
Tuesday, December 29, 2009
I don't need a 'war' to fight my cancer. I need empowering as a patient
O bituaries routinely inform us that so-and-so has died "after a brave battle against cancer".
Of course, we will never read that so-and-so has died "after a pathetically feeble battle against cancer".
Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Mullerian Tumors
Forty-five women (73%) had ovarian cancer, 10 (16%) had peritoneal cancer, four (6%) had fallopian tube cancers, and three (5%) had uterine papillary serous tumors.
Monday, December 28, 2009
Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening
"Our findings reinforce the recommendation that women diagnosed with endometrial cancer before the age of 45 years and women with synchronous endometrial and ovarian cancer be screened for LS, irrespective of family history."
Anthropometric Measures and Risk of Epithelial Ovarian Cancer: Results From the Nurses' Health Study
Anthropometric: understanding human physical variation
Ohio Hospital Program Increases Interaction Between Nurses, Patients
"In October 2008, staff members at Riverside Methodist Hospital (RMH) in Columbus, OH, approached Sheryl Tripp, MSN, RN-BC, nurse manager for the gynecology/gynecology-oncology (gyn/gyn-onc) surgical unit, in hopes of changing the way nurses were issuing patient reports."
Longwoods Healthcare Blog: “What Do Patients Want? A Critical Look at Healthcare Delivery in Canada”
"But the debate, like the health system itself, has been dominated largely by vested interests. I’m watching it, just like you do, from afar. People like the insurance industry and dogmatists from all across the political spectrum – right and left. Rarely in that debate do we hear from patients, or more specifically, from patients without a political agenda or not hired by a group with a message to sell. Rarer still is to hear patients articulate what they want or expect from a health system. And that’s not unique to the US discussion; we have the same problem in Canada...."
Sunday, December 27, 2009
blog: The New Mammogram Guidelines - What You Need to Know (U.S.)
The New Mammogram Guidelines - What You Need to Know
Saturday, December 26, 2009
Friday, December 25, 2009
Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
"THE NECESSITY FOR CLINICAL TRIALS EVALUATING BEVACIZUMAB TREATMENT IN PATIENTS WITH MALIGNANT ASCITES
Based on the preclinical and clinical data outlined above, we strongly suggest that the efficacy and safety of the i.p. application of bevacizumab for the treatment of malignant ascites be assessed in stringently designed clinical studies. Bevacizumab is generally well tolerated and has an acceptable toxicity profile consisting primarily of hypertension and proteinuria. Other rare but important adverse effects, however, include delayed wound healing, arterial thrombosis, and bleeding [118]. Finally, a potentially serious adverse effect of bevacizumab is gastrointestinal perforation and, although comparably infrequent, this potentially life-threatening complication has generated significant clinical interest. Overall, gastrointestinal perforation was found to be an uncommon but well-documented side effect of treatment in the phase III trials of bevacizumab, as well as in subsequent surveillance trials, with a reported incidence of 1%–2% [106, 107, 109, 119]. Though strong evidence identifying specific risk factors is lacking, investigators have urged caution when treating patients with known bowel implants or a large tumor burden, prior radiation, and recent surgery or bowel obstruction [106, 119, 120]."
Subscribe to:
Posts
(
Atom
)
